In particular, the direct targeting of missense mutant p53 proteins (mutp53) at preclinical and clinical levels, and in association with other anti-cancer therapies, is of increasing interest, even if targeted drugs are still at the early stages of development and clinical implementation progressing slowly [81,82,83]. Here, TP53 is linked to cancer.